



Early onset of colorectal cancer in a 13-yearold girl with Lynch syndrome

Do Hee Ahn, MD, Jung Hee Rho, MD, Hann Tchah, MD, In-Sang Jeon, MD, PhD Department of Pediatrics Graduate School of Medicine, Gachon University, Incheon, Korea

Lynch syndrome is the most common inherited colon cancer syndrome. Patients with Lynch syndrome develop a range of cancers including colorectal cancer (CRC) and carry a mutation on one of the mismatched repair (MMR) genes. Although CRC usually occurs after the fourth decade in patients with Lynch syndrome harboring a heterozygous MMR gene mutation, it can occur in children with Lynch syndrome who have a compound heterozygous or homozygous MMR gene mutation. We report a case of CRC in a 13-year-old patient with Lynch syndrome and congenital heart disease. This patient had a heterozygous mutation in *MLH1* (an MMR gene), but no compound MMR gene defects, and a *K-RAS* somatic mutation in the cancer cells.

Key words: Lynch syndrome, Mismatched repair genes, Colorectal neoplasms

Corresponding author: In-Sang Jeon, MD, PhD Department of Pediatrics, Gachon University Gil Medical Center, Graduate School of Medicine, Gachon University, 21 Namdong-daero 774beon-gil, Namdong-gu, Incheon 21565, Korea Tel: +82-32-460-8382 Fax: +82-32-460-8324 E-mail: isieon@oilhospital.com

Received: 24 October, 2014 Revised: 14 May, 2014 Accepted: 21 May, 2014

Introduction

Globally, colorectal cancer (CRC) is the fourth most common cancer in men and the third most common cancer in women¹⁾. Major efforts have focused on understanding the underlying pathogenesis of this common cancer. Although most CRC occurs sporadically, genetic predisposition related to its pathogenesis has been reported²⁾. One of the most investigated genotypic subtypes of CRC is the aberrancy of the mismatch repair pathway, usually found in combination with microsatellite instability (MSI)³⁾. Lynch syndrome, also called hereditary nonpolypsosis colorectal cancer (HNPCC), is caused by germline mutation of mismatch repair (MMR) genes⁴⁾. Individuals affected by Lynch syndrome by heterozygous mutation of MMR usually present CRC in the fourth or fifth decade; however. it is rarely found in teenagers⁵⁾. *K-RAS*, a critical oncogene and its product playing a key role in the kinase signaling growth pathway, plays a critical role in the pathogenesis of CRC⁶⁾.

The revised Bethesda Guidelines recommendations were established for a better understanding and identifying individuals with HNPCC; however, diagnosis of HNPCC at a young age, less than second decades, is difficult as clinician does not suspect it due to its rarity. We recently cared for a female patient with Lynch syndrome, carrying heterozygous *MLH1* germline mutation and *K-RAS* missense somatic mutation; she had CRC at a very early age, 13-years old, and congenital heart disease (transposition of great arteries).

Case report

A 13-year-old Korean female was born without complications. Soon after delivery, she was diagnosed with transposition of great arteries and corrective surgery was performed

Copyright © 2016 by The Korean Pediatric Society

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/ licenses/by-nc/4.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited. at 3 months of age. She grew up without any specific health problem until she reached 12 years of age. At 13 years of age she visited the hospital for weight loss of 10 kg over 2 months and a





Fig. 1. Medium-power view of the tumor shows that neoplastic cells form tortuous and fused glands with desmoplastic reaction. These characteristics are compatible with adenocarcinoma (H&E, ×200).



c.678-1G>C mutation

Fig. 2. DNA sequence analysis of MLH1 reveals a heterozygous splicing mutation, c. 678-1G>C.

pale appearance. She was diagnosed as having Helicobacter pylori gastritis by endoscopy and referred to our hospital for further H. *pylori* eradication and iron supplementation for management of iron deficiency anemia (hemoglobin, 7.1 g/dL; serum iron, 13 µg/dL; total iron-binding capacity, 381 µg/dL; ferritin, 6.50 ng/dL). She did not have any skin lesions such as café-au-lait spots and physical finding was not remarkable. After treatment, she was free from H. pylori gastritis; however, despite taking a sufficient iron supplement for 1 month, iron deficiency persisted without improvement and palpable mass was noticed. For further evaluation of resistant anemia and palpable abdominal mass, colonoscopy was performed and revealed a huge irregular multilobular mass located on the rectum approximately 6 cm from the anal verge. Biopsy was performed at that site and revealed adenocarcinoma of the rectum. CT of the abdomen, pelvis, and chest showed a polypoid mass (2.6 cm×2.5 cm) in the rectum and a huge mass (6.7 cm×5.1 cm) in the transverse colon and ascending colon with lymph node enlargement. Total proctocolectomy with ileal pouch anal anastomosis was performed and stage of cancer was T4N2M0. The histopathologic diagnosis was adenocarcinoma of the colon and rectum (Fig. 1). Genetic study of the pathologic specimen revealed a K-RAS gene mutation at codon 12 as Gly12Asp (c. 35G>A) and MSI was found in cancer cells by polymerase chain reaction amplification and fragment analysis by gene analyzer. Germline mutation study of MMR genes using patient's blood revealed a splicing mutation at MLH1 as c. 678-1G>C while other findings were unremarkable (Fig. 2). Genetic study of her parents was performed and revealed that mother had a same MLH1 mutation of patient; however father had none. In addition, 2 cases of CRC were detected on her maternal relatives (Fig. 3).




Fig. 3. A genetic study showed that the patient and her mother had the same *MLH1* mutation, and two cases of colorectal cancer were found on her maternal side.

After informed consent was obtained, 12 cycles of chemotherapy consisting of oxaliplatin (85 mg/m² on day 1), leucovorin (200 mg/m² on days 1, 2), and 5-fluorouracil (1,500 mg/m² on days 1, 2) (FOLFOX) were completed without any specific problems, with the exception of myelosuppression. Diagnostic workup for recurrence was followed and a suspicious recurrent lesion was noticed at the duodenal second portion and pancreas head portion after completion of the eighth cycle of chemotherapy. After completion of 12 cycles of chemotherapy, imaging study revealed increased mass at the duodenal portion. Supportive management has been provided after chemotherapy and the huge abdominal mass is persistent.

Discussion

Most cancers arise sporadically without apparent causes such as environmental factors or genetic factors. Nonetheless, some cancers arise as the consequence of inherited genetic mutations (germline mutations). Lynch syndrome, caused by germline mutation of MMR genes, such as MLH1, MSH2, MSH6, and PMS2, is an inherited cancer syndrome⁷⁻⁹⁾. Lynch syndrome-related tumors, such as CRC and endometrium tumor in females, and a tumor spectrum comprised of hematological malignancies, brain tumors are frequently developed in patients with Lynch syndrome. In these patients, development of CRC by heterozygous mutation of MMR usually occurs during the fourth or fifth decade. However, in recent years, early onset of CRC has been reported in children with either compound heterozygosity or homozygosity for the *MMR* gene defect¹⁰⁻¹². In our case CRC by heterozygous germline mutation of MMR gene and a point somatic mutation of the K-RAS developed in teenage without compound heterozygosity or homozygosity for the MMR gene defect. Somatic mutation of K-RAS gene, mainly missense mutation at codons 12 and 13, is found less frequently in CRC with Lynch syndrome than sporadic CRC^{13]}. The effect of K-RAS gene mutation on the time of occurrence and prognosis of CRC is uncertain¹⁴. However, it could be considered that the mutation on the growth factor signaling pathway (K-RAS) and MMR gene mutation could contribute synergistically to occurrence of CRC at a very early age. Some studies have also shown that age at diagnosis of CRC decreases in successive generations of Lynch families¹⁵⁾. This could be applied to the early onset of CRC in this case.

Early diagnosis and management of CRC in teenagers with Lynch syndrome is difficult, since occurrence of CRC is very unusual in this period. In our case, diagnosis was delayed and CRC was managed improperly. The necessity of early screening for detection of CRC in subjects with a family history of early onset CRC, even before two decades, should be emphasized.

Conflict of interest

No potential conflict of interest relevant to this article was reported.

References

- 1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
- Power DG, Gloglowski E, Lipkin SM. Clinical genetics of hereditary colorectal cancer. Hematol Oncol Clin North Am 2010;24:837-59.
- Terdiman JP, Gum JR Jr, Conrad PG, Miller GA, Weinberg V, Crawley SC, et al. Efficient detection of hereditary nonpolyposis colorectal cancer gene carriers by screening for tumor microsatellite instability before germline genetic testing. Gastroenterology 2001;120:21-30.
- Marra G, Boland CR. Hereditary nonpolyposis colorectal cancer: the syndrome, the genes, and historical perspectives. J Natl Cancer Inst 1995;87:1114–25.
- Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003;348:919-32.
- Jiang Y, Kimchi ET, Staveley-O'Carroll KF, Cheng H, Ajani JA. Assessment of K-ras mutation: a step toward personalized medicine for patients with colorectal cancer. Cancer 2009;115:3609-17.
- Bronner CE, Baker SM, Morrison PT, Warren G, Smith LG, Lescoe MK, et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 1994;368:258-61.
- Aaltonen LA, Salovaara R, Kristo P, Canzian F, Hemminki A, Peltomäki P, et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 1998;338:1481-7.
- Salovaara R, Loukola A, Kristo P, Kaariainen H, Ahtola H, Eskelinen M, et al. Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol 2000;18:2193-200.
- Plaschke J, Linnebacher M, Kloor M, Gebert J, Cremer FW, Tinschert S, et al. Compound heterozygosity for two MSH6 mutations in a patient with early onset of HNPCC-associated cancers, but without hematological malignancy and brain tumor. Eur J Hum Genet 2006;14:561-6.
- Muller A, Schackert HK, Lange B, Ruschoff J, Fuzesi L, Willert J, et al. A novel MSH2 germline mutation in homozygous state in two brothers with colorectal cancers diagnosed at the age of 11 and 12 years. Am J Med Genet A 2006;140:195-9.
- Poley JW, Wagner A, Hoogmans MM, Menko FH, Tops C, Kros JM, et al. Biallelic germline mutations of mismatch-repair genes: a possible cause for multiple pediatric malignancies. Cancer 2007;109:2349-56.
- Goel A, Nagasaka T, Spiegel J, Meyer R, Lichliter WE, Boland CR. Low frequency of Lynch syndrome among young patients with non-familial colorectal cancer. Clin Gastroenterol Hepatol 2010; 8:966-71.
- Ren J, Li G, Ge J, Li X, Zhao Y. Is K-ras gene mutation a prognostic factor for colorectal cancer: a systematic review and meta-analysis. Dis Colon Rectum 2012;55:913-23.
- Bodas A, Perez-Segura P, Maluenda C, Caldes T, Olivera E, Diaz-Rubio E. Lynch syndrome in a 15-year-old boy. Eur J Pediatr 2008; 167:1213-5.